EMA Authorised: MicardisPlus (telmisartan;hydrochlorothiazide) — Boehringer Ingelheim International GmbH

View source ↗

Summary

MicardisPlus (telmisartan and hydrochlorothiazide) has been authorised by the EMA for hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• MicardisPlus (telmisartan/hydrochlorothiazide)

Snippet

Status: Authorised. Therapeutic area: Hypertension. MAH: Boehringer Ingelheim International GmbH. Decision date: 28/04/2026